4.6 Article

Ubiquitin E3 ligase MID1 inhibits the innate immune response by ubiquitinating IRF3

Journal

IMMUNOLOGY
Volume 163, Issue 3, Pages 278-292

Publisher

WILEY
DOI: 10.1111/imm.13315

Keywords

antiviral response; innate immunity; interferon; IRF3; MID1; ubiquitination

Categories

Funding

  1. National Key R&D Program of China [(2018YFC1705500): 2018YFC1705505]
  2. National Natural Science Foundation of China [31770177, 31970846]
  3. University Natural Science Foundation of Jiangsu Province [18KJA180010]
  4. Medical Health Science and Technology Project of Zhejiang Provincial Health Commission [2020KY368]
  5. Gusu Medical Talent
  6. Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)

Ask authors/readers for more resources

Midline-1 (MID1) is identified as a ubiquitin E3 ligase of IRF3, which downregulates IRF3 protein levels and restricts IFN-I production, thus limiting cellular antiviral response.
Interferon regulatory factor 3 (IRF3) is a critical transcription factor for inducing production of type I interferons (IFN-I) and regulating host antiviral response. Although IRF3 activation during viral infection has been extensively studied, the inhibitory regulation of IRF3 remains largely unexplored. Here, we revealed that Midline-1 (MID1) is a ubiquitin E3 ligase of IRF3 that plays essential roles in regulating the production of IFN-I. We found that MID1 physically interacts with IRF3 and downregulates IRF3 protein levels. Next, we demonstrated that MID1 can induce K48-linked polyubiquitination of IRF3, thus lowing the protein stability of IRF3. Our further studies identified Lys313 as a major ubiquitin acceptor lysine of IRF3 induced by MID1. Finally, MID1-mediated ubiquitination and degradation of IRF3 restrict IFN-I production and cellular antiviral response. This study uncovers a role of MID1 in regulating innate antiviral immunity and may provide a potential target for enhancing host antiviral activity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available